Focus and Scope

American Journal of Hematology/ Oncology, published by U. S. Healthcare Communications LLC.. collaborates with American Medical Association. are dedicated to providing physicians with the best research and important information in the world of medical research and science and to present the information in a format that is understandable and clinically useful. Committed to publishing multidisciplinary research that spans the entire spectrum of healthcare and medicine access, American Journal of Hematology/ Oncology aims at an international audience of pharmacists, clinicians, medical ethicists, regulators, and researchers, providing an online forum for the rapid dissemination of recent research and perspectives in this area.

American Journal of Hematology/ Oncology Evidence seeks to advance clinical trial research and clinical practice by:

• Publishing high-quality studies from the front lines of medical research.
• Challenging the medical community to take new approaches to clinical trial design and execution that yield more powerful clinical evidence.
• Sparking debate and conversation around areas of medicine where clinical decisions are made without sufficient evidence.
• Engaging physicians in a more sophisticated and meaningful way with clinical evidence.

Adhering to the rigorous peer-review and quality standards expected from American Journal of Hematology/ Oncology Evidence publishes:

• Original research, clinical trials, and other clinically grounded work (e.g., epidemiology studies, first-in-human trials, meta-analyses) that validate or challenge prior clinical findings.
• Standard reviews, systematic reviews, and other review types that contextualize research findings with the aim of accelerating clinical adoption of new evidence.
• Case studies and reviews of clinical trial methodology that enhance understanding of trial strengths and weaknesses.
• Curbside consult series that addresses common patient care issues.
• Morning Report series solicited case presentation articles that are delivered in a morning report format.

Generation of Evidence

The process of generating evidence is a key area of focus for American Journal of Hematology/ Oncology Evidence. We encourage readers to evaluate the reasoning behind the complex decisions that investigators make in trial design and execution, and to assess the quality of evidence produced in trials. Our goal is to build a community that takes a rigorous approach to evaluating evidence and assessing its impact on clinical decision-making.

Statistical Methods

American Journal of Hematology/ Oncology Evidence guides readers toward a deeper understanding of the statistical methods used in trials. We provide concise, digestible explanations of research methods to inform the interpretation of the resulting data. In addition, we introduce readers to emerging statistical methods and types of data that will play an increasingly prominent role in future trials.

Multidisciplinary Coverage

American Journal of Hematology/ Oncology Evidence publishes content relevant across all medical disciplines to advance the discussion of how to generate evidence that informs patient care. Physician-scientists, trialists, and general medicine and subspecialty clinicians will all benefit from this publication.

American Journal of Hematology/ Oncology covers themes including, but not limited to:

1. Malignant Hematology (Hematologic Malignancies)

• Leukemias:
• Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL): pathogenesis, molecular subtyping, novel therapeutics, and minimal residual disease (MRD) monitoring.
• Chronic Myeloid Leukemia (CML) and Chronic Lymphocytic Leukemia (CLL): long-term management, tyrosine kinase inhibitor (TKI) therapy, and targeted agents (e.g., BTK, BCL-2 inhibitors).
• Lymphomas:
• Hodgkin Lymphoma: advanced diagnostics, risk-adapted therapy, and management of long-term toxicities.
• Non-Hodgkin Lymphomas (NHL): studies on aggressive lymphomas (e.g., DLBCL) and indolent lymphomas (e.g., Follicular), including novel antibodies and cell-based therapies.
• Plasma Cell Dyscrasias:
• Multiple Myeloma: novel agents (proteasome inhibitors, IMiDs), immunotherapy, and management of precursor conditions (MGUS, smoldering myeloma).
• Waldenström's Macroglobulinemia and AL Amyloidosis.
• Myeloproliferative Neoplasms (MPNs) & Myelodysplastic Syndromes (MDS):
• Pathogenesis, risk stratification, and treatment of polycythemia vera, essential thrombocythemia, and myelofibrosis.
• Management of MDS, including hypomethylating agents and supportive care.

1. Solid Tumor Oncology

• Organ-Specific Cancers: Clinical trials, translational research, and management guidelines for major solid tumors, including:
• Breast Cancer: All subtypes (HR+, HER2+, Triple-Negative), endocrine therapy, targeted agents, and ADCs (antibody-drug conjugates).
• Lung Cancer: Non-small cell (NSCLC) and small cell (SCLC), targeted therapies for driver mutations (EGFR, ALK, etc.), and immunotherapy.
• Gastrointestinal (GI) Cancers: Colorectal, pancreatic, gastric, esophageal, and hepatocellular carcinomas.
• Genitourinary (GU) Cancers: Prostate, bladder, renal cell, and testicular cancers.
• Gynecologic Cancers: Ovarian, endometrial, and cervical cancers.
• Head and Neck Cancers: Multimodality treatment approaches.
• Melanoma and Skin Cancers: Immunotherapy and targeted therapy (BRAF/MEK inhibitors).
• Neuro-Oncology: Primary brain tumors (e.g., glioblastoma).
• Sarcomas: Bone and soft tissue sarcomas.

1. Cancer Therapeutics and Treatment Modalities

• Chemotherapy:
• Clinical trials of novel cytotoxic agents and combination regimens.
• Pharmacology, pharmacokinetics, and pharmacogenomics of chemotherapeutic drugs.
• Immunotherapy:
• Immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4 blockers).
• Cellular therapies: CAR T-cell, TCR, and NK cell therapies.
• Cancer vaccines and oncolytic viruses.
• Targeted Therapy & Precision Medicine:
• Small molecule kinase inhibitors.
• Monoclonal antibodies against tumor-specific antigens.
• Development and application of antibody-drug conjugates (ADCs).
• Radiation Oncology:
• Integration of radiotherapy with systemic treatments.
• Advanced techniques (e.g., SBRT, proton therapy) and studies on their efficacy and toxicity.
• Surgical Oncology:
• Role of surgery in cancer staging, cytoreduction, and cure.
• Neoadjuvant and adjuvant therapy strategies.
• Hematopoietic Stem Cell Transplantation (HSCT):
• Autologous and allogeneic transplantation for hematologic and some solid tumors.
• Management of graft-versus-host disease (GVHD) and other transplant-related complications.
• Endocrine (Hormonal) Therapy:
• Use in hormone-sensitive cancers like breast and prostate cancer.

1. Non-Malignant (Benign) Hematology

• Red Blood Cell Disorders:
• Anemias: iron deficiency, megaloblastic, aplastic, and hemolytic anemias.
• Hemoglobinopathies: Sickle Cell Disease and Thalassemia.
• Coagulation and Thrombosis:
• Bleeding disorders: Hemophilia and von Willebrand Disease.
• Thrombotic disorders: Diagnosis and management of venous thromboembolism (VTE) in cancer and non-cancer patients, thrombophilia.
• Platelet Disorders:
• Immune Thrombocytopenia (ITP) and other causes of thrombocytopenia.
• Thrombocytosis and its management.
• Transfusion Medicine:
• Clinical practices and complications related to blood product transfusion.

1. Foundational Science, Diagnostics, and Prevention

• Cancer Biology and Pathogenesis:
• Molecular mechanisms of carcinogenesis, metastasis, and drug resistance.
• Tumor microenvironment, angiogenesis, and cancer metabolism.
• Genetics, Genomics, and Biomarkers:
• Cancer genetics and predisposition syndromes.
• Genomic, proteomic, and transcriptomic analyses of tumors.
• Discovery and validation of diagnostic, prognostic, and predictive biomarkers.
• Liquid biopsies (ctDNA, circulating tumor cells).
• Diagnostics and Staging:
• Advances in cancer imaging (PET, MRI, CT).
• Molecular pathology, histopathology, and immunohistochemistry.
• Cancer Prevention and Epidemiology:
• Studies on risk factors, chemoprevention, and population-based screening programs.

1. Supportive Care, Survivorship, and Palliative Oncology

• Supportive Care:
• Management of treatment-related toxicities (nausea, mucositis, fatigue, cardiotoxicity).
• Management of cytopenias, including use of hematopoietic growth factors.
• Palliative Oncology and Pain Management:
• Symptom control and quality of life improvement for patients with advanced cancer.
• Integration of palliative care early in the disease course.
• Psycho-Oncology:
• Addressing the psychological, social, and behavioral aspects of cancer.
• Cancer Survivorship:
• Long-term effects of cancer treatment.
• Health and wellness of cancer survivors, including surveillance for recurrence and secondary malignancies.